GIVAX
1 known investors
GIVAX develops a new class of gastrointestinal vaccines using an oral replicating rotavirus vector platform, targeting pathogens such as norovirus and rotavirus. Its pipeline includes a combined rotavirus/norovirus pediatric vaccine, an adult norovirus vaccine, and potential vaccines for other GI pathogens like C. difficile.
Investors · 1
Frequently asked questions
- What does GIVAX do?
- GIVAX develops a new class of gastrointestinal vaccines using an oral replicating rotavirus vector platform, targeting pathogens such as norovirus and rotavirus. Its pipeline includes a combined rotavirus/norovirus pediatric vaccine, an adult norovirus vaccine, and potential vaccines for other GI pathogens like C. difficile.
- Who are GIVAX's investors?
- GIVAX's investors include RA Capital.